Indication · Metabolic disease
Type 2 diabetes
Also known as: T2D · type 2 diabetes mellitus
Type 2 diabetes has 15 mapped peptide assets across 3 targets.
Targets
View all →GLP-1R
Activates incretin signaling to potentiate glucose-dependent insulin secretion, delay gastric emptying, and reduce appetite.
GIPR
Mediates GIP-dependent insulin secretion; co-agonism with GLP-1R is thought to enhance weight loss and glycemic control.
Glucagon receptor
Activation increases hepatic glucose output and energy expenditure; biased/co-agonist approaches aim to preserve lipid oxidation and satiety without hyperglycemia.
Active assets by stage
View all →| Asset | Stage | Sponsors |
|---|---|---|
| Tirzepatide | Approved | Eli Lilly |
| Semaglutide | Approved | Novo Nordisk |
| Retatrutide | Phase 3 | Eli Lilly |
| Cagrisema | Phase 3 | Novo Nordisk |
| Mazdutide | Phase 3 | Eli Lilly |
| Danuglipron | Phase 2 | Pfizer |
| Survodutide | Phase 2 | Boehringer Ingelheim, Zealand Pharma |
| Maritide | Phase 1/2 | Amgen |
| CT-388 | Phase 1 | Roche |
| GSBR-1290 | Phase 2 | Structure Therapeutics |
| Orforglipron | Phase 3 | Eli Lilly |
| Pemvidutide | Phase 2 | Eli Lilly |
| Efinopegdutide | Phase 2 | Eli Lilly |
| Oral semaglutide | Approved | Novo Nordisk |
Discontinuations
| Asset | Stage | Sponsors |
|---|---|---|
| Lotiglipron | Discontinued | Pfizer |
Trials
View all →| Registry ID | Phase | Title | Status |
|---|---|---|---|
| NCT03954834 | Phase 3 | A Study of Tirzepatide (LY3298176) Compared With Semaglutide in Participants With Type 2 Diabetes | Completed |
| NCT04159132 | Phase 3 | A Study of Tirzepatide for the Treatment of Obesity or Overweight in Participants Without Type 2 Diabetes | Completed |
| NCT04184622 | Phase 3 | A Research Study to Look at How Semaglutide Works Compared to Placebo in People With Overweight or Obesity | Completed |
| NCT05567796 | Phase 3 | A Study of Retatrutide in Participants With Obesity or Overweight | Recruiting |
| NCT05929066 | Phase 3 | A Study to Evaluate the Effect of CagriSema on Body Weight in Adults Living With Overweight or Obesity | Active, not recruiting |
| NCT05564117 | Phase 2 | A Study of Danuglipron in Participants With Type 2 Diabetes | Completed |
| Pfizer-lotiglipron-Ph2 | Phase 2 | A Study of Lotiglipron in Participants With Type 2 Diabetes | Terminated |
| NCT05649174 | Phase 2 | A Study to Evaluate Survodutide in Participants With Non-alcoholic Steatohepatitis (NASH) | Active, not recruiting |
| NCT03548935 | Phase 1 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 133 in Adult Subjects With Overweight/Obesity | Completed |
| Roche-CT388-Ph1 | Phase 1 | A Study of CT-388 in Participants With Obesity or Overweight | Recruiting |
| StructureTx-GSBR1290-Ph1 | Phase 1 | A Study of GSBR-1290 in Healthy Participants and Participants With Type 2 Diabetes | Completed |
| Lilly-orforglipron-Ph3 | Phase 3 | A Study of Orforglipron in Participants With Obesity or Overweight | Recruiting |
Readouts
View all →Clinical trial registry and NEJM publication
Tirzepatide SURPASS-2 delivers superior HbA1c and weight reductions vs semaglutide 1 mg
Clinical trial registry and NEJM publication
Semaglutide 2.4 mg achieves 14.9% mean weight loss in STEP 1
Clinical trial registry and conference presentation
Retatrutide phase 2 shows up to 24.2% mean weight loss at 48 weeks
ClinicalTrials.gov record and conference abstract